Queue, a Silicon Valley pharmacy robotics startup, has secured $12.6 million in seed funding led by AlleyCorp, bringing the company’s total raised to $18.6 million including a $6 million pre-seed round from Riot Ventures. The funding represents a significant bet on automation technology designed to address one of healthcare’s most persistent problems: the collapse of pharmacy operations under the weight of labor shortages and impossible economics. Queue’s autonomous robotic system fills and verifies prescriptions from sealed wholesale pill bottles into filled, verified prescription vials, handling 250 of the most commonly prescribed medications in the U.S. The startup has moved beyond proof-of-concept into real-world deployment.
A working prototype is already operational at a major national pharmacy chain, marking a critical milestone for a company still in early stages. This isn’t theoretical engineering—pharmacists and technicians at a chain location are using Queue’s system to process actual prescriptions, generating data on what works and what doesn’t in a high-volume retail setting. The timing of this funding isn’t accidental. Pharmacy technician vacancies stand at 40 percent or higher across the country, forcing chains to cut hours, close locations, and leave stores understaffed during peak times. Queue’s founders are betting that robots can be faster and more reliable than hiring enough humans in a market where trained technicians are increasingly scarce.
Table of Contents
- Why Pharmacy Automation Has Become a Startup Opportunity
- What Queue’s Technology Actually Does (and Doesn’t)
- Who’s Betting on Queue and Why These Investors Matter
- How Pharmacy Chains Lose Money (and Why Queue Addresses It)
- Why Deploying Robots in Pharmacies Is Harder Than It Looks
- Nick Desai: From Heal to Queue’s Next Bet
- The Technical Foundation from Tesla and Zipline
- Frequently Asked Questions
Why Pharmacy Automation Has Become a Startup Opportunity
The pharmacy industry sits at an inflection point where automation has become not just appealing but necessary. Over the past five years, major chains have experienced a cascade of closures tied directly to technician shortages. Pharmacies that once employed four technicians per shift now operate with two, compressing the window when customers can get prescriptions filled and creating obvious safety risks when workers are overextended. What makes Queue’s entry different is that pharmacy robotics isn’t new—compounding robots and pill counters have existed for years. But those systems required manual loading, human verification, and significant integration complexity.
Queue’s system is designed to operate more autonomously, pulling directly from existing supply chains and handling both the physical work of filling and the verification step that currently consumes technician time. The distinction matters because verification is where errors are caught; automating it requires getting the vision and logic absolutely right. The market size justifies the investment. There are roughly 70,000 retail pharmacy locations in the U.S., and each one deals with the same shortage and cost crisis. If Queue can prove its system works reliably enough to scale, the addressable market is enormous. But that’s also why pharmacy chains haven’t rushed to deploy robots—they need to see sustained performance under real conditions, not just a successful pilot.
What Queue’s Technology Actually Does (and Doesn’t)
Queue’s system operates in a specific slice of the pharmacy workflow. It takes sealed bottles of pills from wholesale suppliers, identifies the medication and strength using vision systems, and dispenses the correct number of pills into prescription vials. It then verifies the count and applies labels. This handles the repetitive, high-volume work that currently eats up technician time—work that’s tedious but where errors are costly. The limitation here is significant: Queue’s robots support 250 medications, which covers common drugs but excludes specialty medications, biologics, and compounded prescriptions. These excluded categories represent a slice of pharmacy business, and they still require human handling.
The implication is that Queue’s system works best in high-volume community pharmacies filling standard medications, not in specialty or clinical settings. A small independent pharmacy filling compounded prescriptions, or a hospital pharmacy managing complex oncology meds, has a different problem to solve. The verification step is technically complex in ways that matter. The robot doesn’t just count pills—it uses imaging to confirm it grabbed the right medication (not a visually similar one), that the count is correct, and that nothing is damaged or stuck. This is the part that replaces the technician glancing at the bottle, counting by hand, and double-checking the label. getting this right is the difference between a useful tool and a system that creates liability.
Who’s Betting on Queue and Why These Investors Matter
The seed round included AlleyCorp as the lead, with additional backing from House Capital, Ubiquity Ventures, Grep Ventures, and Banter Capital. The investor list hints at the thesis driving the round. AlleyCorp focuses on logistics and supply chain optimization—the kind of investors who care about moving pills efficiently through networks. Ubiquity Ventures invests in infrastructure and automation. This isn’t a roster of generalist VCs hoping something sticks; it’s investors who understand operational scaling. Riot Ventures’ presence in the pre-seed is also notable.
Riot has concentrated on healthcare infrastructure and logistics startups, backing companies that solve unglamorous but essential problems in broken systems. Their $6 million pre-seed investment signals confidence in Queue’s founders and initial technical progress. The follow-on seed from AlleyCorp and others suggests those early results held up under scrutiny—that the prototype didn’t just work once, but demonstrated consistent performance. The composition of the investor group also reflects what Queue is selling: not consumer innovation, but efficiency and cost reduction for a major industry facing existential pressure. Pharmacy chains don’t adopt new technology for excitement; they adopt it to survive. The investors backing Queue understand they’re funding infrastructure for a healthcare segment that desperately needs it.
How Pharmacy Chains Lose Money (and Why Queue Addresses It)
A single unfilled prescription costs a pharmacy chain money in multiple ways. There’s the lost sale, the customer who takes their business elsewhere, and the staff overtime required to meet demand. A busy chain pharmacy might fill 300-500 prescriptions daily with a team stretched thin. Every technician absent for vacation or sick leave creates a backlog that spreads across remaining staff. The economics are brutal. A technician earns $30,000 to $40,000 annually in many markets, and the shortage means competing for hires against other chains, hospitals, and clinics. Train someone for six months, and they leave for a job with better hours.
Meanwhile, labor costs for pharmacy operations typically run 50-60 percent of operating expenses, making technician wages one of the single largest cost drivers. Removing that cost via automation is theoretically transformative—if the robot can fill prescriptions faster and more reliably than hiring another full-time technician. The tradeoff Queue creates is between capital expenditure and labor costs. A pharmacy chain needs to purchase or lease Queue’s robots, integrate them with pharmacy systems, and train staff to operate and maintain them. That upfront capital commitment must be justified by labor savings or increased volume that doesn’t happen without additional staff. For large chains, the math likely works; for small independents, it probably doesn’t. This creates a dynamic where Queue’s technology could accelerate consolidation in pharmacy, as large chains gain efficiency advantages.
Why Deploying Robots in Pharmacies Is Harder Than It Looks
The prototype deployment with a major chain is impressive, but it’s also a carefully controlled environment. A single location with supportive management, dedicated space, and staff who understand they’re piloting new technology behaves differently than a typical store. Generalizing from one site to dozens or hundreds of locations involves unexpected complexity. Pharmacy systems vary wildly. Some chains use proprietary software that doesn’t integrate smoothly with new hardware. Some locations have different physical layouts. Technician workflow varies by site—what works in one store might be inefficient in another.
There’s also the cultural piece: staff resistance to automation is real. Technicians might worry about job security, or simply resist change. In settings where staffing is already low, removing a technician’s duties without removing the technician creates friction. The other challenge is medication supply continuity. Queue’s system works with sealed wholesale bottles, but supply chains for specific medications are fragile. If a medication is backordered or temporarily unavailable, the robot can’t work around it the way a technician can. The system’s reliability is only as good as the supply of medications it’s designed to fill. Any disruption upstream cascades through the automation.
Nick Desai: From Heal to Queue’s Next Bet
Queue’s CEO is Nick Desai, who previously founded Heal, a home healthcare company that raised over $200 million and scaled to operate across multiple U.S. cities. Heal dispatched healthcare providers to patients’ homes for urgent care, solving both sides of a matching problem: patients who wanted convenient care and providers who needed flexible work. It was fundamentally a logistics business dressed in healthcare clothes.
Desai’s track record matters for Queue’s credibility with investors and chains. He’s demonstrated the ability to build hardware-enabled operations at scale, navigate healthcare regulation, and convince large institutions to adopt new workflows. Heal faced skepticism initially—why would patients trust an unfamiliar provider showing up at home?—but Desai and his team built enough trust and performance to attract serious capital. That pattern repeats with Queue. He’s running another infrastructure play in healthcare, again in a space where current processes are broken enough that alternatives feel risky but necessary.
The Technical Foundation from Tesla and Zipline
Co-founder Liu brings engineering depth from two companies that care deeply about robotics and autonomous systems. Tesla’s manufacturing operations depend on robots that coordinate with humans, scale production, and integrate into complex supply chains. Zipline builds autonomous drones for medical delivery in Africa, a business that requires robotics to work reliably in high-stakes environments where failure isn’t an option.
These backgrounds are directly relevant to Queue’s challenges. Pharmacy automation needs robustness at Tesla scale and reliability at Zipline intensity. The co-founder combination—Liu handling the technical depth of robotics and verification systems, Desai managing the business of convincing chains to deploy—represents a reasonable split of expertise. Liu understands what it takes to build a robot that works reliably; Desai understands how to commercialize it in an industry skeptical of new things.
Frequently Asked Questions
What medications can Queue’s system handle?
Queue’s technology supports 250 of the most commonly prescribed medications in the U.S. Specialty drugs, biologics, and compounded prescriptions are not part of the system’s current scope.
Has Queue’s system been tested in a real pharmacy?
Yes. A working prototype is deployed with a major national pharmacy chain, processing actual prescriptions.
Who are Queue’s investors?
The $12.6 million seed round is led by AlleyCorp with backing from House Capital, Ubiquity Ventures, Grep Ventures, and Banter Capital. Riot Ventures led the $6 million pre-seed.
What problem is Queue solving?
Pharmacy technician vacancies are at 40% or higher, forcing chains to cut hours and close locations. Queue automates prescription filling and verification to reduce dependence on scarce technician labor.
How much total funding has Queue raised?
The company has raised $18.6 million to date, including the $6 million pre-seed and $12.6 million seed round.
Is queue’s technology designed to eliminate technician jobs?
Queue’s system handles filling and verification, work currently done by technicians. It reduces labor demand but doesn’t necessarily eliminate technician roles, particularly as chains face shortages that create other tasks requiring human attention.